Representatives for Gaithersburg biotech company MedImmune hinted at an expansion of their campus at a mayor and council work session Monday evening.

Medimmune Executive Vice President of Operations Andy Skibo mentioned a “need to reassess how space is divided” on MedImmune’s Gaithersburg campus. “There are no specific construction plans at this time,” he said, though the company is working on a master plan with the city.

The company houses about two-thirds of its research centers in Gaithersburg, Skibo said. MedImmune was awarded LEED Gold certification for its new 308,000-square-foot research and development laboratory in August, according to a company press release.

According to a city of Gaithersburg spokesperson, it is the city’s largest private employer, with about 2,300 employees. MedImmune plans to hire about 50 more employees at the Gaithersburg campus within the next year and a half, said MedImmune Director of Corporate Public Relations Tracy Rossin.

In the long term, the company is gearing up for an “enormous undertaking,” Skibo said. They plan to accelerate production and release one product per year, creating a new industry standard, while generating $5 billion in revenues, Skibo said.

“You have one of the largest players in the industry in your backyard, and we’re proud of it,” Skibo said.

Gaithersburg Mayor Sidney Katz and several council members expressed their satisfaction with their local rising star.

“Gaithersburg is very proud of the fact that MedImmune calls Gaithersburg home,” Katz said.

The city council’s vice president, Ryan Spiegel, called the meeting “a pride-fest, as well it should be.” He and council member Jud Ashman said the city stands ready to help the company.

Among other treatments, MedImmune discovered and developed the technology behind a vaccine that prevents human papillomavirus, or HPV, Skibo said. The vaccine cures a virus that can lead to cancer. The company is owned by London biopharmaceutical giant AstraZeneca.